163 related articles for article (PubMed ID: 26163548)
1. Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
Chudasama VL; Ovacik MA; Abernethy DR; Mager DE
J Pharmacol Exp Ther; 2015 Sep; 354(3):448-58. PubMed ID: 26163548
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
3. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
Ramakrishnan V; Mager DE
J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
[TBL] [Abstract][Full Text] [Related]
4. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
[TBL] [Abstract][Full Text] [Related]
5. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
7. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
10. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
Park J; Bae EK; Lee C; Choi JH; Jung WJ; Ahn KS; Yoon SS
BMB Rep; 2014 May; 47(5):274-9. PubMed ID: 24286313
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
13. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.
Luo P; Lin M; Lin M; Zhu D; Wang Z; Shen J; Yang B; He Q
Pharmazie; 2010 Mar; 65(3):213-8. PubMed ID: 20383943
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.
Malara N; Focà D; Casadonte F; Sesto MF; Macrina L; Santoro L; Scaramuzzino M; Terracciano R; Savino R
Cell Cycle; 2008 Oct; 7(20):3235-45. PubMed ID: 18931595
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
17. [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
Zhang XY; Bai QX; Huang GS; Zhao H; Chen JJ; Yang LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):684-8. PubMed ID: 21729550
[TBL] [Abstract][Full Text] [Related]
18. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
Que W; Li S; Chen J
Mol Med Rep; 2013 May; 7(5):1641-5. PubMed ID: 23545701
[TBL] [Abstract][Full Text] [Related]
19. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Morelli MB; Offidani M; Alesiani F; Discepoli G; Liberati S; Olivieri A; Santoni M; Santoni G; Leoni P; Nabissi M
Int J Cancer; 2014 Jun; 134(11):2534-46. PubMed ID: 24293211
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
